Home
About
Overview
Sharing Data
ORCID
Help
History (2)
Effectiveness of Ustekinumab Dose Escalation in Patients With Crohn's Disease.
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials.
See All 2 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Effectiveness of Ustekinumab Dose Escalation in Patients With Crohn's Disease.
Effectiveness of Ustekinumab Dose Escalation in Patients With Crohn's Disease. Clin Gastroenterol Hepatol. 2021 01; 19(1):104-110.
View in:
PubMed
subject areas
C-Reactive Protein
Crohn Disease
Humans
Leukocyte L1 Antigen Complex
Remission Induction
Retrospective Studies
Severity of Illness Index
Ustekinumab
authors with profiles
Joel Pekow
David Rubin
Russell Cohen
Sushila Dalal